CN107709333B - 羟基酯衍生物、其制备方法以及含有它们的药物组合物 - Google Patents

羟基酯衍生物、其制备方法以及含有它们的药物组合物 Download PDF

Info

Publication number
CN107709333B
CN107709333B CN201680036383.5A CN201680036383A CN107709333B CN 107709333 B CN107709333 B CN 107709333B CN 201680036383 A CN201680036383 A CN 201680036383A CN 107709333 B CN107709333 B CN 107709333B
Authority
CN
China
Prior art keywords
phenyl
formula
oxy
pyrimidin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680036383.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107709333A (zh
Inventor
Z·斯拉维克
A·科斯基
M·尚里翁
D·德马勒斯
O·热内斯特
J·E·P·戴维森
J·B·穆雷
S·赛博思
A·帕克扎尔
B·巴兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furnalis R&d Co ltd
Laboratoires Servier SAS
Original Assignee
Furnalis R&d Co ltd
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furnalis R&d Co ltd, Laboratoires Servier SAS filed Critical Furnalis R&d Co ltd
Publication of CN107709333A publication Critical patent/CN107709333A/zh
Application granted granted Critical
Publication of CN107709333B publication Critical patent/CN107709333B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201680036383.5A 2015-06-23 2016-06-22 羟基酯衍生物、其制备方法以及含有它们的药物组合物 Active CN107709333B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1555752 2015-06-23
PCT/EP2016/064433 WO2016207225A1 (en) 2015-06-23 2016-06-22 New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
CN107709333A CN107709333A (zh) 2018-02-16
CN107709333B true CN107709333B (zh) 2021-01-01

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680036383.5A Active CN107709333B (zh) 2015-06-23 2016-06-22 羟基酯衍生物、其制备方法以及含有它们的药物组合物

Country Status (43)

Country Link
US (2) US10227358B2 (enExample)
EP (1) EP3313851B1 (enExample)
JP (1) JP6741697B2 (enExample)
KR (1) KR102718253B1 (enExample)
CN (1) CN107709333B (enExample)
AR (1) AR105103A1 (enExample)
AU (1) AU2016282836B2 (enExample)
BR (1) BR112017027414B1 (enExample)
CA (1) CA2990088C (enExample)
CL (1) CL2017003258A1 (enExample)
CO (1) CO2017012786A2 (enExample)
CR (1) CR20170564A (enExample)
CU (1) CU20170160A7 (enExample)
CY (1) CY1122542T1 (enExample)
DK (1) DK3313851T3 (enExample)
EA (1) EA033266B1 (enExample)
EC (1) ECSP17081744A (enExample)
ES (1) ES2759480T3 (enExample)
FR (1) FR3037957B1 (enExample)
GE (1) GEP20207074B (enExample)
HK (1) HK1249506A1 (enExample)
HR (1) HRP20200107T1 (enExample)
HU (1) HUE047889T2 (enExample)
IL (1) IL256270A (enExample)
JO (1) JO3675B1 (enExample)
MA (1) MA42239B1 (enExample)
MD (1) MD3313851T2 (enExample)
MX (1) MX372716B (enExample)
MY (1) MY190561A (enExample)
PE (1) PE20180742A1 (enExample)
PH (1) PH12017502246A1 (enExample)
PL (1) PL3313851T3 (enExample)
PT (1) PT3313851T (enExample)
RS (1) RS59904B1 (enExample)
RU (1) RU2734418C2 (enExample)
SI (1) SI3313851T1 (enExample)
SV (1) SV2017005587A (enExample)
TN (1) TN2017000511A1 (enExample)
TW (1) TWI604844B (enExample)
UA (1) UA122228C2 (enExample)
UY (1) UY36736A (enExample)
WO (1) WO2016207225A1 (enExample)
ZA (1) ZA201708460B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
GEP20227372B (en) * 2017-01-06 2022-04-25 Novartis Ag Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ES2971466T3 (es) * 2017-06-22 2024-06-05 Servier Lab Combinación de un inhibidor de Mcl-1 y un tratamiento estándar de atención para cánceres hematológicos, usos y composiciones farmacéuticas de la misma
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
BR112020003163A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
LT3891156T (lt) * 2018-12-06 2023-12-27 Les Laboratoires Servier Tienopirimidino, kaip mcl-1 inhibitoriaus, naujos kristalinės formos
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
CN114746428B (zh) * 2019-10-03 2025-05-16 加利福尼亚技术学院 Mcl1抑制剂及其应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN117651554A (zh) 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464667A (zh) * 2010-11-03 2012-05-23 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
CN104011054A (zh) * 2011-11-15 2014-08-27 森申有限公司 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类
CN104725397A (zh) * 2013-12-23 2015-06-24 法国施维雅药厂 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1675861B1 (en) * 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
UA100262C2 (uk) * 2008-03-05 2012-12-10 Метилген Інк. Інгібітори активності протеїнтирозинкінази
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464667A (zh) * 2010-11-03 2012-05-23 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
CN104011054A (zh) * 2011-11-15 2014-08-27 森申有限公司 用作钾通道抑制剂的噻吩并和呋喃并嘧啶类和吡啶类
CN104725397A (zh) * 2013-12-23 2015-06-24 法国施维雅药厂 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers;William Kemnitzer，等;《Bioorganic & Medicinal Chemistry Letters》;20090505;第19卷;第3536-3540页 *

Also Published As

Publication number Publication date
MX372716B (es) 2020-05-28
PL3313851T3 (pl) 2020-05-18
PT3313851T (pt) 2020-01-06
MY190561A (en) 2022-04-27
SI3313851T1 (sl) 2020-03-31
RU2018102365A3 (enExample) 2019-09-23
PH12017502246B1 (en) 2018-05-28
UA122228C2 (uk) 2020-10-12
HK1254657A1 (en) 2019-07-26
RS59904B1 (sr) 2020-03-31
RU2018102365A (ru) 2019-07-23
SV2017005587A (es) 2018-04-11
US20190161496A1 (en) 2019-05-30
US20180170947A1 (en) 2018-06-21
CU20170160A7 (es) 2018-05-08
EA201890125A1 (ru) 2018-06-29
CO2017012786A2 (es) 2018-04-10
PH12017502246A1 (en) 2018-05-28
PE20180742A1 (es) 2018-04-27
UY36736A (es) 2016-12-30
AU2016282836B2 (en) 2020-07-09
MD3313851T2 (ro) 2020-02-29
TWI604844B (zh) 2017-11-11
HUE047889T2 (hu) 2020-05-28
GEP20207074B (en) 2020-03-10
AR105103A1 (es) 2017-09-06
AU2016282836A1 (en) 2018-01-18
CR20170564A (es) 2018-02-20
CL2017003258A1 (es) 2018-06-01
ES2759480T3 (es) 2020-05-11
IL256270A (en) 2018-02-28
JO3675B1 (ar) 2020-08-27
US10711010B2 (en) 2020-07-14
CA2990088A1 (en) 2016-12-29
ZA201708460B (en) 2021-06-30
CN107709333A (zh) 2018-02-16
CA2990088C (en) 2021-04-13
BR112017027414B1 (pt) 2023-12-19
KR20180019223A (ko) 2018-02-23
KR102718253B1 (ko) 2024-10-16
BR112017027414A2 (pt) 2018-08-28
FR3037957A1 (enExample) 2016-12-30
EA033266B1 (ru) 2019-09-30
WO2016207225A1 (en) 2016-12-29
DK3313851T3 (da) 2020-01-27
NZ738455A (en) 2024-03-22
EP3313851B1 (en) 2019-11-06
JP6741697B2 (ja) 2020-08-19
CY1122542T1 (el) 2021-01-27
ECSP17081744A (es) 2018-02-28
FR3037957B1 (fr) 2019-01-25
EP3313851A1 (en) 2018-05-02
TN2017000511A1 (en) 2019-04-12
TW201709911A (zh) 2017-03-16
RU2734418C2 (ru) 2020-10-16
US10227358B2 (en) 2019-03-12
MX2017016997A (es) 2018-09-07
MA42239B1 (fr) 2020-02-28
HRP20200107T1 (hr) 2020-04-03
JP2018522855A (ja) 2018-08-16
HK1249506A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
CN107709333B (zh) 羟基酯衍生物、其制备方法以及含有它们的药物组合物
CN108602841B (zh) 新的铵衍生物、它们的制备方法以及含有它们的药物组合物
KR102620905B1 (ko) 신규한 아미노산 유도체, 이의 제조방법, 및 이를 함유한 약제 조성물
CN108137497B (zh) 新的二环衍生物、其制备方法以及含有它们的药物组合物
CN107922432B (zh) 新的羟基酸衍生物、其制备方法以及含有它们的药物组合物
HK1259781A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
OA18889A (en) New Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK1254872A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
HK1254657B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249506

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1249506

Country of ref document: HK